Skin Cancer and Hyperthermia and Radiotherapy

Inclusion Criteria:

• Personally signed and dated written informed consent

• Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basalcell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation

• ≥ T2 (TNM Classification 8th Edition)

• Tumor thickness up to 2cm (Maximum Depth invasion and/or exophytic growth, measuredon pathology report or imaging)

• Local recurrence allowed, if primary treatment longer ago than 6 months (afterprimary treatment other than radiotherapy (RT))

• Age ≥ 65 years

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with a lifeexpectancy of more than 6 months

• Presentation at the Swiss Hyperthermia Network (SHN) tumor conference mandatory

Exclusion Criteria:

• Other histology than BCC or SCC

• T1 tumor and/or N+ (according to TNM classification 8th edition)

• Tumors after resection (R1 or R2 as well as adjuvant indication)

• Tumor invasion into critical areas

• Several lesions exceeding the capacity of one treatment/radiation field (multiplelesions within one treatment field are acceptable)

• Previous (one month) or concurrent Chemo- or Immunotherapy

• Patients with connective tissue disorders (e.g. Sclerodermia, Lupus erythematodes)

• Lesions inside or in proximity (within 3cm) previously irradiated area

• Medical immunosuppression

• wIRA-specific exclusion criteria

• Tattoos in irradiated area

• Increased photosensitivity (either due to simultaneous treatment withphotosensitivity-enhancing medications or conditions such as porphyria)